Yuji Tabata
Chuo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Structure-activity relationship studies of ME1111, a novel antifungal agent for topical treatment of onychomycosis.
Journal: The Journal of antibiotics
Published: September 11, 2024
Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis.
Journal: The Journal of antibiotics
Published: December 03, 2023
ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
Journal: European journal of pharmacology
Published: May 30, 2023
The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages.
Journal: Biochemistry and biophysics reports
Published: June 26, 2021
Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Journal: European journal of pharmacology
Published: March 09, 2021
A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung.
A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung.
Journal: European journal of pharmacology
Published: July 30, 2020
In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.
Journal: Antimicrobial agents and chemotherapy
Published: April 13, 2017
Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis.
Journal: Antimicrobial agents and chemotherapy
Published: July 28, 2015
Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Journal: Antimicrobial agents and chemotherapy
Published: July 27, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026